RSV vaccine + hMPV vaccine + PIV3 vaccine

RSV vaccine + hMPV vaccine + PIV3 vaccine is an investigational combination vaccine formulated to provide immunization against three major respiratory viruses: respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3)[1][2][3][4][5][6][7][8]. These vaccine candidates, including Clover's SCB-1033 and Vicebio/Sanofi's VXB-251 and SP-0291, use either protein subunit prefusion F (PreF-Trimer) antigens or mRNA-based technology to stimulate robust neutralizing antibody responses against all three viral targets, aiming to fill gaps left by monovalent RSV vaccines and to offer broad coverage in older adults[1][3][4][5][6][8]. Mechanistically, they act as immunostimulants, triggering the adaptive immune system via antigen presentation of stabilized viral surface proteins, utilizing Trimer-Tag (Clover) or Molecular Clamp (Vicebio/Sanofi) platforms[1][5][6]. Development is led for prevention in older adults, targeting significant morbidity from seasonal co-circulation of these viruses[1][2][4][5][6][7][8].

Other names

RSV/hMPV/PIV3 vaccineTrivalent RSV-hMPV-PIV3 vaccineRSV+hMPV+PIV3 combination vaccine